

Table S15.1 CpG sites methylation level of IGF2 in CHD patients and healthy individuals

Groups	SampleID	CpG_1	CpG_2	CpG_3	CpG_4.5	CpG_6	CpG_7	CpG_8
Control	1	0.3	0.63	0.62	0.47	0.62	0.36	0.7
	2	0.5	0.73	0.6	0.49	0.6	0.54	0.76
	3							
	4							
	5	0.41	0.66	0.58	0.58	0.58	0.36	0.78
	6							
	7	0.55	0.53	0.57	0.49	0.57	0.4	0.96
	8	1	0.5	0.64	0.41	0.64	0.38	0.43
	9	0.41	0.75	0.59	0.38	0.59	0.54	0.71
	10							
	11							
	12	0.44	0.45	0.59	0.5	0.59	0.37	0.78
	13							
	14	0.46	1	0.54	0.61	0.54	0.54	0.52
	15							
	16	0.41	0.39	0.58	0.48	0.58	0.47	0.86
	17	0.56	0.84	0.68	0.65	0.68	0.89	0.71
	18	0.5	0.78	0.64	0.57	0.64	0.37	0.68
	19							
	20							
	21	0.4	0.77	0.59	0.53	0.59	0.39	0.87
	22							
	23	0.5	0.73	0.64	0.51	0.64	0.49	0.8
	24	0.36	0.69	0.59	0.55	0.59	0.33	0.69
	25	0.29	1	0.56	0.54	0.56	0.4	0.72
	26	0.48	0.71	0.61	0.61	0.61	0.52	0.78
	27	0.36	0.93	0.63	0.9	0.63	0.64	0.65
	28							
CHD	1	0.6	0.76	0.66	0.58	0.66	0.53	0.77
	2	0.49	0.73	0.61	0.58	0.61	0.45	0.66
	3							
	4	0.51	0.75	0.6	0.6	0.6	0.47	0.75
	5	0.52	0.74	0.63	0.55	0.63	0.46	0.77
	6	0.41	0.7	0.59	0.68	0.59	0.38	0.71
	7	0.3	0.68	0.56	0.44	0.56	0.38	0.66
	8	0.28	0.58	0.53	0.62	0.53	0.34	0.43
	9	0.65	0.87	0.66	0.63	0.66	0.69	0.84
	10							
	11							
	12	0.43	0.73	0.65	0.54	0.65	0.45	0.71
	13	0.49	0.63	0.6	0.52	0.6	0.98	0.69
	14	0.34	0.82	0.57	0.49	0.57	0.36	0.69
	15	0.49	0.76	0.64	0.53	0.64	0.45	0.74
	16	0.43	0.7	0.55	0.52	0.55	0.41	0.74
	17	0.27	0.63	0.54	0.55	0.54	0.24	0.54
	18	0.39	0.86	0.58	0.49	0.58	0.39	0.75

19	0.51	0.9	0.68	0.62	0.68	0.59	0.77
20							
21							
22							
23	0.41	0.83	0.67	0.49	0.67	0.43	0.63
24							
25	0.12	0.66	0.78	1	0.78	0.12	0.12
26							
27	0.51	0.72	0.59	0.58	0.59	0.46	0.72

Table S15.2 CpG sites methylation level of IGF2 in CHD patients and healthy individuals

Groups	SampleID	CpG_9.10.11	CpG_12.13	CpG_14	CpG_15.16	CpG_17	CpG_18	CpG_19
Control	1	0.55	0.83	0.69	0.64	0.8	0.68	0.43
	2	0.46	0.53	0.48	0.49	0.62	0.61	0.46
	3							
	4							
	5	0.63	0.54	0.77	0.72	0.83	0.73	0.53
	6							
	7	0.47	0.52	0.47	0.62	0.67	0.58	0.55
	8	0.43	0.56	0.47	0.52	0.7	0.62	0.58
	9	0.64	0.7	0.69	0.6	0.82	0.69	0.41
	10							
	11							
	12	0.48	0.61	0.53	0.63	0.72	0.7	0.33
	13							
	14	0.45	0.61	0.6	0.59	0.74	0.69	0.44
	15							
	16	0.51	0.53	0.61	0.58	0.71	0.68	1
	17	0.46	0.52	0.51	0.63	0.74	0.7	0.42
	18	0.54	0.6	0.61	0.63	0.77	0.71	0.42
	19							
	20							
	21	0.48	0.59	0.58	0.63	0.77	0.72	0.55
	22							
CHD	23	0.44	0.47	0.47	0.53	0.62	0.62	0.38
	24	0.53	0.71	0.58	0.67	0.74	0.73	0.46
	25	0.41	0.5	0.41	0.59	0.56	0.61	0.4
	26	0.44	0.46	0.37	0.56	0.52	0.57	0.43
	27	0.52	0.56	0.57	0.65	0.74	0.69	0.48
	28							
	1	0.62	0.76	0.65	0.65	0.83	0.7	0.46
	2	0.57	0.54	0.55	0.65	0.67	0.68	0.37
	3							
	4	0.5	0.54	0.53	0.62	0.72	0.66	0.36
	5	0.48	0.45	0.49	0.56	0.73	0.63	0.5
	6	0.43	0.47	0.49	0.51	0.69	0.6	0.52
	7	0.46	0.47	0.47	0.53	0.64	0.6	0.52
	8	0.55	0.7	0.6	0.64	0.77	0.7	0.52
	9	0.57	0.61	0.59	0.66	0.8	0.69	0.59
	10							
	11							
	12	0.4	0.48	0.54	0.53	0.61	0.63	0.61
	13	0.42	0.49	0.53	0.46	0.64	0.54	0.45
	14	0.62	0.66	0.63	0.69	0.81	0.72	0.42
	15	0.46	0.55	0.57	0.57	0.73	0.65	0.51
	16	0.48	0.52	0.51	0.57	0.68	0.61	0.5
	17	0.58	0.6	0.56	0.69	0.8	0.68	0.37
	18	0.5	0.51	0.54	0.58	0.7	0.64	0.51

19	0.6	0.78	0.62	0.66	0.76	0.7	0.49
20							
21							
22							
23	0.4	0.43	0.53	0.53	0.6	0.56	0.37
24							
25	0.5	0.58	0.43	0.57	0.73	0.62	0.3
26							
27	0.62	0.66	0.66	0.73	0.81	0.77	0.37

Table S15.3 CpG sites methylation level of IGF2 in CHD patients and healthy individuals

Groups	SampleID	CpG_20	CpG_21.22	CpG_23	CpG_24.25	CpG_26	CpG_27
Control	1	0.44	0.46	0.64	0.66	0.64	0.69
	2	0.39	0.4	0.55	0.5	0.55	0.59
	3						
	4						
	5	0.43	0.53	0.66	0.63	0.66	0.72
	6						
	7	0.43	0.47	0.64	0.63	0.64	0.72
	8	0.36	0.51	0.62	0.64	0.62	0.7
	9	0.38	0.41	0.64	0.63	0.64	0.75
	10						
	11						
	12	0.36	0.39	0.61	0.6	0.61	0.69
	13						
	14	0.37	0.44	0.62	0.65	0.62	0.71
	15						
	16	0.43	0.56	0.68	0.61	0.68	0.73
	17	0.44	0.43	0.62	0.62	0.62	0.7
	18	0.46	0.5	0.65	0.69	0.65	0.64
	19						
	20						
	21	0.45	0.56	0.68	0.79	0.68	0.74
	22						
	23	0.44	0.38	0.63	0.64	0.63	0.73
	24	0.4	0.43	0.62	0.65	0.62	0.71
	25	0.38	0.36	0.58	0.58	0.58	0.62
	26	0.36	0.39	0.54	0.53	0.54	0.65
	27	0.41	0.57	0.58	0.6	0.58	0.65
	28						
CHD	1	0.51	0.6	0.73	0.76	0.73	0.8
	2	0.43	0.51	0.64	0.66	0.64	0.71
	3						
	4	0.46	0.34	0.56	0.53	0.56	0.64
	5	0.42	0.54	0.65	0.68	0.65	0.75
	6	0.36	0.47	0.55	0.55	0.55	0.6
	7	0.43	0.55	0.61	0.66	0.61	0.67
	8	0.5	0.48	0.68	0.68	0.68	0.74
	9	0.5	0.63	0.69	0.72	0.69	0.77
	10						
	11						
	12	0.48	0.6	0.66	0.69	0.66	0.77
	13	0.39	0.48	0.64	0.66	0.64	0.68
	14	0.38	0.43	0.61	0.57	0.61	0.69
	15	0.45	0.42	0.62	0.6	0.62	0.69
	16	0.39	0.5	0.63	0.7	0.63	0.67
	17	0.34	0.45	0.61	0.64	0.61	0.6
	18	0.44	0.5	0.59	0.59	0.59	0.63

19	0.39	0.45	0.68	0.58	0.68	0.73
20						
21						
22						
23	0.43	0.46	0.6	0.55	0.6	0.63
24						
25	0.35	0.41	0.59	0.55	0.59	0.7
26						
27	0.36	0.49	0.59	0.6	0.59	0.62

---